A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies

Tomoko Matsumoto; Keiji Nogami; Kenichi Ogiwara; Midori Shima

doi:10.1160/TH11-05-0331

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2012; 107(02): 288-301
DOI: 10.1160/TH11-05-0331

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies

Authors

Tomoko Matsumoto

¹Department of Pediatrics, Nara Medical University, Kashihara, Japan
Keiji Nogami

¹Department of Pediatrics, Nara Medical University, Kashihara, Japan
Kenichi Ogiwara

¹Department of Pediatrics, Nara Medical University, Kashihara, Japan
Midori Shima

¹Department of Pediatrics, Nara Medical University, Kashihara, Japan

Abstract

Summary

Acquired haemophilia A (AHA) is caused by the development of factor (F)VIII autoantibodies, demonstrating type 1 or type 2 inhibitory behaviour, and results in more serious haemorrhagic symptoms than in congenital severe HA. The reason(s) for this remains unknown, however. The global coagulation assays, thrombin generation tests and clot waveform analysis, demonstrated that coagulation parameters in patients with AHA-type 2 inhibitor were more significantly depressed than those in patients with moderate HA with similar FVIII activities. Thrombin and intrinsic FXa generation tests were significantly depressed in AHA-type 1 and AHA-type 2 compared to severe HA, and more defective in AHA-type 1 than in AHA-type 2. To investigate these inhibitory mechanism(s), anti-FVIII autoantibodies were purified from AHA plasmas. AHA-type 1 autoantibodies, containing an anti-C2 ESH4-epitope, blocked FVIII(a)-phospholipid binding, whilst AHA-type 2, containing an anti-C2 ESH8-epitope, inhibited thrombin-catalysed FVIII activation. The coagulation function in a reconstituted AHA-model containing exogenous ESH4 or ESH8 was more abnormal than in severe HA. The addition of anti-FIX antibody to FVIII-deficient plasma resulted in lower coagulation function than its absence. These results support the concept that global coagulation might be more suppressed in AHA than in severe HA due to the inhibition of FIXa-dependent FX activation by steric hindrance in the presence of FVIII-anti-C2 autoantibodies. Additionally, AHA-type 1 inhibitors prevented FVIIIa-phospholipid binding, essential for the tenase complex, whilst AHA-type 2 antibodies decreased FXa generation by inhibiting thrombin-catalysed FVIII activation. These two distinct mechanisms might, in part, contribute to and exacerbate the serious haemorrhagic symptoms in AHA.

Presented in abstract form at the 52nd annual meeting of the American Society of Hematology, Orlando, Florida, USA, December 6, 2010.

Keywords

Acquired haemophilia A - anti-C2 autoantibody - thrombin generation - tenase complex - FXa generation

Volltext

Referenzen

References
1 Mann KG, Nesheim ME, Church WR. et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
2 Hoyer LW.. The factor VIII complex: structure and function. Blood 1981; 58: 1-13.
3 Wood WI, Capon DJ, Simonsen CC. et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337.
4 Eaton D, Rodriguez H, Vehar GA.. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
5 Fay PJ.. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
6 Nogami K, Shima M, Matsumoto T. et al. Mechanisms of plasmin-catalyzed inactivation of factor VIII: a crucial role for proteolytic cleavage at Arg336 responsible for plasmin-catalyzed factor VIII inactivation.. J Biol Chem 2007; 282: 5287-5295.
7 Gawryl MS, Hoyer LW.. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982; 60: 1103-1109.
8 Prescott R, Nakai H, Saenko EL. et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89: 3663-3671.
9 Meeks SL, Healey JF, Parker ET. et al. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007; 110: 4234-4242.
10 Meeks SL, Healey JF, Parker ET. et al. Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.. Blood 2008; 112: 1151-1153.
11 Andersson LO, Brown JE.. Interaction of factor VIII-von Willebrand factor with phospholipid vesicles. Biochem J 1981; 200: 161-167.
12 Scandella D, Gilbert GE, Shima M. et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-1819.
13 Shima M, Nakai H, Scandella D. et al. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Haematol 1995; 91: 714-721.
14 Nogami K, Shima M, Nishiya K. et al. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism.. Thromb Haemost 2002; 87: 459-465.
15 Hoffmann M, Monroe DM.. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
16 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma.. Pathophysiol Haemost Thromb 2003; 33: 4-15.
17 Braun PJ, Givens TB, Stead AG. et al. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thromb Haemost 1997; 78: 1079-1087.
18 Matsumoto T, Shima M, Takeyama M. et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.. J Thromb Haemost 2006; 4: 377-384.
19 Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008; 14 (Suppl. 03) 83-92.
20 Matsumoto T, Nogami K, Ogiwara K. et al. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.. Int J Hematol 2009; 90: 576-582.
21 Collins PW, Hirsch S, Baglin TP. et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.. Blood 2007; 109: 1870-1877.
22 Griffin BD, Micklem LR, McCann MC. et al. The production and characterisation of a panel of ten murine monoclonal antibodies to human procoagulant factor VIII. Thromb Haemost 1986; 55: 40-46.
23 Yoshioka A, Giddings JC, Thomas JE. et al. Immunoassays of factor IX antigen using monoclonal antibodies. Br J Haematol 1985; 59: 265-275.
24 Mimms LT, Zampighi G, Nozaki Y. et al. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20: 833-840.
25 Nogami K, Wakabayashi H, Schmidt K. et al. Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa.. J Biol Chem 2003; 278: 1634-1641.
26 Pipe SW, Kaufman RJ.. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851-11856.
27 Takeshima K, Smith C, Tait J. et al. The preparation and phospholipid binding property of the C2 domain of human factor VIII.. Thromb Haemost 2003; 89: 788-794.
28 Shima M, Scandella D, Yoshioka A. et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-246.
29 Bradford MM.. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
30 Kasper CK, Aledort LM, Aronson D. et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872.
31 Suzuki H, Shima M, Arai M. et al. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes. Thromb Haemost 1997; 77: 862-867.
32 Lollar P, Fay PJ, Fass DN.. Factor VIII and factor VIIIa. Methods Enzymol 1993; 222: 128-143.
33 Saenko EL, Shima M, Rajalakshmi KJ. et al. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601-11605.
34 Nogami K, Shima M, Hosokawa K. et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689.. J Biol Chem 2000; 275: 25774-25780.
35 Saenko EL, Shima M, Gilbert GE. et al. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 1996; 271: 27424-27431.
36 Ngo JC, Huang M, Roth DA. et al. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.. Structure 2008; 16: 597-606.
37 Nogami K, Saenko EL, Takeyama M. et al. Identification of a thrombin-interactive site within the FVIII A2 domain that is responsible for the cleavage at Arg372.. Br J Haematol 2008; 140: 433-443.
38 Soeda T, Nogami K, Nishiya K. et al. The factor VIIIa C2 domain (residues 2228-2240) interacts with the factor IXa Gla domain in the factor Xase complex.. J Biol Chem 2009; 284: 3379-3388.
39 Lollar P, Hill-Eubanks DC, Parker CG.. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263: 10451-10455.
40 Schulman S, Eelde A, Holmström M. et al. Validation of a composite score for clinical severity of hemophilia.. J Thromb Haemost 2008; 6: 1113-1121.
41 Tagariello G, Iorio A, Santagostino E. et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders.. Blood 2009; 114: 779-784.